Hederagenin Induces Apoptosis in Cisplatin-Resistant Head and Neck Cancer Cells by Inhibiting the Nrf2-ARE Antioxidant Pathway

<div>A model of the proposed mechanism of hederagenin in cisplatin-resistant HNC cells. Hederagenin selectively induces apoptosis in cancer cells by promoting ROS production and GSH depletion via inhibition of the Nrf2-ARE pathway.</div>

Oxidative Medicine and Cellular Longevity

fig7

Figure 7

Figure 7: Hederagenin Induces Apoptosis in Cisplatin-Resistant Head and Neck Cancer Cells by Inhibiting the Nrf2-ARE Antioxidant Pathway 